Global trial scale Emmes operates across 90+ countries with 32,000 trial sites, indicating strong capacity for large, global studies. This presents opportunities to engage sponsors seeking international reach, complex trial execution, and centralized data management.

Therapeutic depth Specialized expertise in oncology, cell and gene therapy, vaccines, viral infectious diseases, and ophthalmology suggests a credible partner for sponsors pursuing advanced therapies or programs requiring specialized clinical operations, biostatistics, and regulatory support.

Tech enabled delivery Embedded purpose-built technology and AI across operations, data management, patient engagement, and trial oversight offer a selling point for sponsors prioritizing data quality, efficiency, and faster decision-making in complex trials.

Global public health & partnerships Experience supporting government and non-profit organizations alongside biopharma enables Emmes to position for collaborations on public health initiatives, vaccine programs, and studies with varied funding and regulatory requirements.

Mid-market growth potential With revenue in the $100M-$250M range and a mid-to-large employee base, Emmes may present an attractive alternative to larger CROs for mid-market sponsors seeking scalable, high-quality trial execution with specialized capabilities and competitive pricing.